D M Nguyen

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Induction of apoptosis in malignant pleural mesothelioma cells by activation of the Fas (Apo-1/CD95) death-signal pathway
    John H Stewart
    National Institutes of Health, National Cancer Institute, Thoracic Oncology Section, Surgery Branch, Bethesda, MD 20892, USA
    J Thorac Cardiovasc Surg 123:295-302. 2002
  2. pmc Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01
    W S Yeow
    Section of Thoracic Oncology, Surgery Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA
    Br J Cancer 94:1436-45. 2006
  3. ncbi request reprint Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin
    D M Nguyen
    Section of Thoracic Oncology, Surgery Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1502, USA
    J Thorac Cardiovasc Surg 118:908-15. 1999
  4. ncbi request reprint The essential role of the mitochondria-dependent death-signaling cascade in chemotherapy-induced potentiation of Apo2L/TRAIL cytotoxicity in cultured thoracic cancer cells: amplified caspase 8 is indispensable for combination-mediated massive cell death
    Dao M Nguyen
    Section of Thoracic Oncology, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cancer J 12:257-73. 2006
  5. ncbi request reprint Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway
    Dao M Nguyen
    Section of Thoracic Oncology, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Thorac Cardiovasc Surg 125:1132-42. 2003
  6. ncbi request reprint Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis
    D M Nguyen
    Section of Thoracic Oncology and Surgical Metabolism, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Ann Thorac Surg 72:371-8; discussion 378-9. 2001
  7. ncbi request reprint Lung cancer staging in the genomics era
    Dao M Nguyen
    Section of Thoracic Oncology, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Room 4 W 4 3940, 10 Center Drive, Bethesda, MD 20892, USA
    Thorac Surg Clin 16:329-37. 2006
  8. ncbi request reprint The role of the mitochondria in mediating cytotoxicity of anti-cancer therapies
    Dao M Nguyen
    Section of Thoracic Oncology, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Room 4W 4 3940, 10 Center Drive, Bethesda, MD 29892, USA
    J Bioenerg Biomembr 39:13-21. 2007
  9. ncbi request reprint Modulation of metastasis phenotypes of non-small cell lung cancer cells by 17-allylamino 17-demethoxy geldanamycin
    D M Nguyen
    Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Ann Thorac Surg 70:1853-60. 2000
  10. ncbi request reprint Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway
    Dao M Nguyen
    Section of Throacic Oncology, Surgery Branch, Center for Cancer Research, National Cancer Center, National Institutes of Health, Bethesda, MD, USA
    J Thorac Cardiovasc Surg 127:365-75. 2004

Collaborators

Detail Information

Publications45

  1. ncbi request reprint Induction of apoptosis in malignant pleural mesothelioma cells by activation of the Fas (Apo-1/CD95) death-signal pathway
    John H Stewart
    National Institutes of Health, National Cancer Institute, Thoracic Oncology Section, Surgery Branch, Bethesda, MD 20892, USA
    J Thorac Cardiovasc Surg 123:295-302. 2002
    ....
  2. pmc Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01
    W S Yeow
    Section of Thoracic Oncology, Surgery Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA
    Br J Cancer 94:1436-45. 2006
    ..Combinations of VA with either a PKC inhibitor or an NF-kappaB inhibitor are promising novel molecularly targeted therapeutics for thoracic cancers...
  3. ncbi request reprint Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin
    D M Nguyen
    Section of Thoracic Oncology, Surgery Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1502, USA
    J Thorac Cardiovasc Surg 118:908-15. 1999
    ..The aim of this study was to investigate whether depletion of the erbB-2 gene product (p185) by 17-allylamino 17-demethoxygeldanamycin would sensitize lung cancer cells to paclitaxel (Taxol) in vitro...
  4. ncbi request reprint The essential role of the mitochondria-dependent death-signaling cascade in chemotherapy-induced potentiation of Apo2L/TRAIL cytotoxicity in cultured thoracic cancer cells: amplified caspase 8 is indispensable for combination-mediated massive cell death
    Dao M Nguyen
    Section of Thoracic Oncology, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cancer J 12:257-73. 2006
    ....
  5. ncbi request reprint Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway
    Dao M Nguyen
    Section of Thoracic Oncology, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Thorac Cardiovasc Surg 125:1132-42. 2003
    ....
  6. ncbi request reprint Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis
    D M Nguyen
    Section of Thoracic Oncology and Surgical Metabolism, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Ann Thorac Surg 72:371-8; discussion 378-9. 2001
    ..This project was designed to evaluate the tumoricidal and antiangiogeneic effects of 17-AAG and paclitaxel in H358 non-small cell lung cancer cells grown as xenografts in nude mice...
  7. ncbi request reprint Lung cancer staging in the genomics era
    Dao M Nguyen
    Section of Thoracic Oncology, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Room 4 W 4 3940, 10 Center Drive, Bethesda, MD 20892, USA
    Thorac Surg Clin 16:329-37. 2006
    ....
  8. ncbi request reprint The role of the mitochondria in mediating cytotoxicity of anti-cancer therapies
    Dao M Nguyen
    Section of Thoracic Oncology, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Room 4W 4 3940, 10 Center Drive, Bethesda, MD 29892, USA
    J Bioenerg Biomembr 39:13-21. 2007
    ..The aim of this article is to provide an overview of the role of the mitochondria, an energy-generating organelle essential for life, in mediating death when properly activated by cytotoxic stresses...
  9. ncbi request reprint Modulation of metastasis phenotypes of non-small cell lung cancer cells by 17-allylamino 17-demethoxy geldanamycin
    D M Nguyen
    Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Ann Thorac Surg 70:1853-60. 2000
    ....
  10. ncbi request reprint Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway
    Dao M Nguyen
    Section of Throacic Oncology, Surgery Branch, Center for Cancer Research, National Cancer Center, National Institutes of Health, Bethesda, MD, USA
    J Thorac Cardiovasc Surg 127:365-75. 2004
    ....
  11. doi request reprint Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway
    S Shamimi-Noori
    Section of Thoracic Oncology, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Cancer Gene Ther 15:356-70. 2008
    ..The CDDP/AdVgTRAIL combination also exhibits a strong antitumor effect in in vivo animal model of human cancer xenografts...
  12. ncbi request reprint Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1
    T S Weiser
    Thoracic Oncology Section, Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892-1502, USA
    J Immunother 24:151-61. 2001
    ..Although the mechanisms have not been fully defined, sequential DAC-DP treatment may be a novel strategy to augment antitumor immunity in cancer patients...
  13. ncbi request reprint Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells
    Y Kang
    Thoracic Oncology Section, Surgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892 1201, USA
    Oncogene 26:4394-403. 2007
    ..Collectively, these findings suggest that BORIS recruits Sp1 to mediate de-repression of NY-ESO-1 during pulmonary carcinogenesis...
  14. ncbi request reprint Targets for molecular intervention in multistep pulmonary carcinogenesis
    D S Schrump
    Thoracic Oncology Section, Surgery Branch, National Cancer Institute, National Institutes of Health, Building 10, Room 2B 07, 10 Center Drive, Bethesda, Maryland 20892 1502, USA
    World J Surg 25:174-83. 2001
    ..This review summarizes the molecular biology of lung cancers in relation to the prognosis and treatment of patients with these neoplasms...
  15. ncbi request reprint Enhancement of Apo2L/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin
    Wilson S Tsai
    Section of Thoracic Oncology, Surgery Branch, Center for Cancer Research, National Cancer Institute, NIH, Room 4 4W 3940, 10 Center Drive, Bethesda, MD 20892 1502, USA
    Mol Cancer Ther 5:2977-90. 2006
    ....
  16. ncbi request reprint Gossypol, a phytochemical with BH3-mimetic property, sensitizes cultured thoracic cancer cells to Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand
    Wen Shuz Yeow
    Section of Thoracic Oncology, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Thorac Cardiovasc Surg 132:1356-62. 2006
    ..This study was designed to evaluate whether gossypol, a phytochemical compound with BH3-mimetic property that functions as an inhibitor of Bcl2/BclXL, would sensitize cultured thoracic cancer cells to this death-inducing ligand...
  17. ncbi request reprint Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondria-mediated caspase activation cascade
    Rishindra M Reddy
    Section of Thoracic Oncology, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Apoptosis 12:55-71. 2007
    ..These finding form the basis for further development of HDAC inhibitors + Apo2L/TRAIL combination as novel targeted therapy for thoracic malignancies...
  18. ncbi request reprint Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura
    David S Schrump
    Thoracic Oncology Section Surgery Branch, Cancer Therapy Evaluation Program, National Cancer Institute NIH, 10 Center Drive, Bethesda, MD 20892, USA
    Clin Cancer Res 12:5777-85. 2006
    ..A phase I trial was done to examine pharmacokinetics, toxicities, and gene expression mediated by 5-aza-2'-deoxycytidine (DAC) in patients with thoracic malignancies...
  19. ncbi request reprint Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228
    Xiaodan Yu
    Thoracic Oncology Section, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Natl Cancer Inst 94:504-13. 2002
    ..This study evaluated the mechanisms by which FK228 mediates apoptosis in non-small-cell lung cancer (NSCLC) cells...
  20. pmc Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation
    M Firdos Ziauddin
    Section of Thoracic Oncology, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Neoplasia 8:446-57. 2006
    ..These findings provide a rationale for the development of VA and Apo2L/TRAIL combination as a novel molecular therapeutic for thoracic cancers...
  21. ncbi request reprint Targeting the epigenome for the treatment of thoracic malignancies
    David S Schrump
    Thoracic Oncology Section, Surgery Branch, Center for Cancer Research, National Cancer Institute, Room 4 3940, 10 Center Drive, MSC 1201, Bethesda, MD 20892 1201, USA
    Thorac Surg Clin 16:367-77, vi. 2006
    ..Further analysis of molecular response in tumor tissues following exposure to chromatin remodeling agents may enable us to identify novel mechanisms pertaining to lung cancer epigenetics, and design more efficacious regimens...
  22. pmc Lung cysts, spontaneous pneumothorax, and genetic associations in 89 families with Birt-Hogg-Dubé syndrome
    Jorge R Toro
    Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20892 7231, USA
    Am J Respir Crit Care Med 175:1044-53. 2007
    ..Birt-Hogg-Dubé syndrome (BHDS) is an autosomal, dominantly inherited genodermatosis that predisposes to fibrofolliculomas, kidney neoplasms, lung cysts, and spontaneous pneumothorax...
  23. ncbi request reprint Images in cardiothoracic surgery. Active malignant pleural effusion captured through the thoracoscope
    Ajay V Maker
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Ann Thorac Surg 80:1941. 2005
  24. ncbi request reprint Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells
    Xiao Dan Yu
    Department of Pathology, Institute of Basic Medical Sciences, Beijing, China
    Cancer J 13:105-13. 2007
    ..In the present study we sought to further define the mechanisms by which FK228 modulates oncoprotein signaling and to ascertain whether altered signal transduction contributes to FK228-mediated apoptosis in lung cancer cells...
  25. ncbi request reprint The essential role of the mitochondria and reactive oxygen species in Cisplatin-mediated enhancement of fas ligand-induced apoptosis in malignant pleural mesothelioma
    John H Stewart
    Department of Surgery, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA
    J Surg Res 141:120-31. 2007
    ..This mechanistic study establishes a the translational framework for the clinical application of sequential CDDP/sFasL in the treatment of MPM...
  26. doi request reprint Clinical and molecular responses in lung cancer patients receiving Romidepsin
    David S Schrump
    Thoracic Oncology Section Surgery Branch, Center for Cancer Research and Cancer Therapy Evaluation Program, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Clin Cancer Res 14:188-98. 2008
    ..A phase II trial was done to examine clinical and molecular responses mediated by this histone deacetylase inhibitor in lung cancer patients...
  27. ncbi request reprint Induction of apoptosis of lung and esophageal cancer cells treated with the combination of histone deacetylase inhibitor (trichostatin A) and protein kinase C inhibitor (calphostin C)
    Justin B Maxhimer
    Section of Thoracic Oncology, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1502, USA
    J Thorac Cardiovasc Surg 129:53-63. 2005
    ....
  28. ncbi request reprint Suppression of pro-metastasis phenotypes expression in malignant pleural mesothelioma by the PI3K inhibitor LY294002 or the MEK inhibitor UO126
    George W Cole
    Section of Thoracic Oncology, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Anticancer Res 26:809-21. 2006
    ....
  29. ncbi request reprint Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells
    Dao M Nguyen
    Thoracic Oncology Section, Surgery Branch, and Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1502, USA
    Clin Cancer Res 10:1813-25. 2004
    ..The present study was undertaken to examine the effects of the histone deacetylase inhibitor, Depsipeptide (DP) FK228, in conjunction with the cyclin-dependent kinase inhibitor, Flavopiridol (FLA), in cultured MPM cells...
  30. ncbi request reprint Growth factor receptors as targets for lung cancer therapy
    Dao M Nguyen
    Section of Thoracic Oncology, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Semin Thorac Cardiovasc Surg 16:3-12. 2004
    ....
  31. ncbi request reprint Cisplatin enhances apoptosis induced by a tumor-selective adenovirus expressing tumor necrosis factor-related apoptosis-inducing ligand
    Rishindra M Reddy
    Section of Thoracic Oncology, Surgery Branch, Center for Cancer Research, National Cancer Institute NIH, Bethesda, MD 20892, USA
    J Thorac Cardiovasc Surg 128:883-91. 2004
    ..Pretreatment of TRAIL-resistant cells with cisplatin sensitizes them to this ligand. Cisplatin also has been shown to enhance adenoviral transgene expression...
  32. ncbi request reprint Utilization of chromatin remodeling agents for lung cancer therapy
    David S Schrump
    Thoracic Oncology Section, Surgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892 1201, USA
    Cancer J 13:56-64. 2007
    ....
  33. ncbi request reprint Sequential 5-Aza 2'-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells
    Federico A Steiner
    Thoracic Oncology Section, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1201, USA
    Oncogene 24:2386-97. 2005
    ..Furthermore, induction of TFPI-2 may be a useful surrogate marker of treatment response in individuals receiving sequential DAC/DP infusions...
  34. ncbi request reprint The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro
    George W Cole
    Section of Thoracic Oncology, Surgery Branch, Center for Cancer Research, National Cancer Institute NIH, 10 Center Drive, Bethesda, MD 20892, USA
    J Thorac Cardiovasc Surg 129:1010-7. 2005
    ..The purpose of this study is to evaluate the ability of the epidermal growth factor receptor tyrosine kinase inhibitor PD153035 to abrogate the expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro...
  35. ncbi request reprint Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells
    Julie A Hong
    Thoracic Oncology Section, Surgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892 1201, USA
    Cancer Res 65:7763-74. 2005
    ....
  36. ncbi request reprint Depletion of DNA methyltransferase 1 and/or DNA methyltransferase 3b mediates growth arrest and apoptosis in lung and esophageal cancer and malignant pleural mesothelioma cells
    Edmund S Kassis
    Thoracic Oncology Section, Surgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    J Thorac Cardiovasc Surg 131:298-306. 2006
    ..The present study was undertaken to examine the effects of antisense-mediated inhibition of DNMT expression in cultured thoracic malignancies...
  37. pmc De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model
    Z Sheng Guo
    Thoracic Oncology Section and Tumor Immunology Section, Surgery Branch, National Cancer Institute NIH, Bethesda, MD 20892, USA
    Cancer Res 66:1105-13. 2006
    ..These data show a novel strategy of combined chemoimmunotherapy of cancer targeting a CTA induced de novo in a broad range of tumor histologies, and support further evaluation of chromatin-remodeling agents for human cancer therapy...
  38. ncbi request reprint Novel molecular targeted therapy for esophageal cancer
    David S Schrump
    Thoracic Oncology Section, Surgery Branch, National Cancer Institute, Bldg 10, Rm 4 3490, 10 Center Drive MSC 1201, Bethesda, MD 20892, USA
    J Surg Oncol 92:257-61. 2005
    ....
  39. ncbi request reprint Pharmacokinetics of paclitaxel administered by hyperthermic retrograde isolated lung perfusion techniques
    David S Schrump
    Thoracic Oncology Section, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1502, USA
    J Thorac Cardiovasc Surg 123:686-94. 2002
    ....
  40. ncbi request reprint Targeting the epigenome for the treatment and prevention of lung cancer
    David S Schrump
    Thoracic Oncology Section, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892 1201, USA
    Semin Oncol 32:488-502. 2005
    ..These data support additional investigations pertaining to the epigenetics of lung cancer, and the evaluation of chromatin remodeling agents for the treatment and prevention of this disease...
  41. ncbi request reprint Virtual bronchoscopy for evaluation of airway disease
    Steven E Finkelstein
    Thoracic Oncology Section, Surgery Branch, Center for Cancer Research, National Cancer Institute, Building 10, Room 2B 07, 10 Center Drive, National Institutes of Health, Bethesda, MD 20892 1502, USA
    Thorac Surg Clin 14:79-86. 2004
    ....
  42. ncbi request reprint Spectral fluorescence molecular imaging of lung metastases targeting HER2/neu
    Yoshinori Koyama
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892 1088, USA
    Clin Cancer Res 13:2936-45. 2007
    ....
  43. ncbi request reprint Incorporation and integration of implanted myogenic and stem cells into native myocardial fibers: anatomic basis for functional improvements
    Edgar G Chedrawy
    Division of Cardiac Surgery, McGill University Health Center, Montreal, Quebec, Canada
    J Thorac Cardiovasc Surg 124:584-90. 2002
    ..For implanted cells to actually contribute to the synchronous contractions of the heart, however, they must be anatomically integrated with the existing native myocardial fibers...
  44. ncbi request reprint Novel thoracic imaging augments diagnosis of bronchial obstruction
    Steven E Finkelstein
    National Institutes of Health, Bethesda, Maryland 20892, USA
    Ann Thorac Surg 76:296. 2003
  45. ncbi request reprint Virtual bronchoscopy for evaluation of malignant tumors of the thorax
    Steven E Finkelstein
    Thoracic Oncology Section, Surgery Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892 1502, USA
    J Thorac Cardiovasc Surg 123:967-72. 2002
    ..This study was undertaken to evaluate the diagnostic potential of virtual bronchoscopy by comparing virtual bronchoscopic images with fiberoptic bronchoscopic findings in patients with thoracic malignant disease...